Quantum-Si incorporated ( QSI ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Risa Lindsay Jeffrey Hawkins - President, CEO & Director Jeffry Keyes - CFO & Treasurer Conference Call Participants Alexander Vukasin - Canaccord Genuity Corp., Research Division Scott Henry - Alliance Global Partners, Research Division Swayampakula Ramakanth - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good day, and thank you for standing by.
Quantum-Si Incorporated (QSI) came out with a quarterly loss of $0.17 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.18 per share a year ago.
Quantum-Si incorporated (NASDAQ:QSI ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Jeffrey Alan Hawkins - President, CEO & Director Jeffry R. Keyes - CFO & Treasurer Risa Lindsay - Corporate Participant Conference Call Participants Kyle Alexander Mikson - Canaccord Genuity Corp., Research Division Scott Robert Henry - Alliance Global Partners, Research Division Swayampakula Ramakanth - H.C.
| Biotechnology Industry | Healthcare Sector | Jeffrey Alan Hawkins CEO | NASDAQ (NMS) Exchange | 74765K105 CUSIP |
| US Country | 149 Employees | - Last Dividend | - Last Split | 10 Jun 2021 IPO Date |
Quantum-Si Incorporated is at the forefront of life sciences innovation, focusing on the development of a cutting-edge single-molecule detection platform designed to revolutionize Next Generation Protein Sequencing (NGPS). Their groundbreaking technology aims to provide deeper insights into protein identification, characterizing protein variants, antibody characterization, biomarker identification, and the analysis of post-translational modifications. Since its inception in 2013, Quantum-Si has established itself in Branford, Connecticut, where it continues to push the boundaries of protein sequencing technology.